We have located links that may give you full text access.
The Neutrophil to Lymphocyte Ratio in Heart Failure: A Comprehensive Review.
Romanian Journal of Internal Medicine 2019 July 13
INTRODUCTION: Heart failure (HF) and systemic inflammation are interdependent processes that continuously potentiate each other. Distinct pathophysiological pathways are activated, resulting in increased neutrophil count and reduced lymphocyte numbers, making the neutrophil to lymphocyte ratio (NLR) a potential indirect marker of severity. We conducted this comprehensive review to characterize the role of NLR in HF.
METHODS: We searched the PubMed (MEDLINE) database using the key words neutrophil", "lymphocyte", "heart failure", "cardiomyopathy", "implantable cardioverter defibrillator", "cardiac resynchronization therapy" and "heart transplant".
RESULTS: We identified 241 publications. 31 were selected for this review, including 12107 patients. NLR was correlated to HF severity expressed by clinical, biological, and imaging parameters, as well as to short and long-term prognosis. Most studies reported its survival predictive value. Elevated NLR (>2.1-7.6) was an independent predictor of in-hospital mortality [adjusted HR 1.13(95%CI 1.01-1.27)-2.8(95%CI 1.43-5.53)] as well as long-term all-cause mortality [adjusted HR 1.43(95%CI 1.1-1.85) -2.403(95%CI 1.076-5.704)]. Higher NLR levels also predicted poor functional capacity [NLR>2.26/2.74, HR 3.93(95%CI 1.02-15.12)/3.085(95%CI 1.52-6.26)], hospital readmissions [NLR>2.9/7.6, HR 1.46(95%CI 1.10-1.93)/3.46(95%CI 2.11-5.68)] cardiac resynchronization therapy efficacy [NLR>3.45/unit increase, HR 12.22(95%CI 2.16-69.05)/1.51(95%CI 1.01-2.24)] and appropriate implantable cardioverter defibrillator shocks (NLR>2.93), as well as mortality after left ventricular assist device implantation [NLR>4.4/quartiles, HR 1.67 (95%CI 1.03-2.70)/1.22 (95%CI 1.01-1.47)] or heart transplant (NLR>2.41, HR 3.403(95%CI 1.04-11.14)].
CONCLUSION: Increased NLR in HF patients can be a valuable auxiliary biomarker of severity, and most of all, of poor prognosis.
METHODS: We searched the PubMed (MEDLINE) database using the key words neutrophil", "lymphocyte", "heart failure", "cardiomyopathy", "implantable cardioverter defibrillator", "cardiac resynchronization therapy" and "heart transplant".
RESULTS: We identified 241 publications. 31 were selected for this review, including 12107 patients. NLR was correlated to HF severity expressed by clinical, biological, and imaging parameters, as well as to short and long-term prognosis. Most studies reported its survival predictive value. Elevated NLR (>2.1-7.6) was an independent predictor of in-hospital mortality [adjusted HR 1.13(95%CI 1.01-1.27)-2.8(95%CI 1.43-5.53)] as well as long-term all-cause mortality [adjusted HR 1.43(95%CI 1.1-1.85) -2.403(95%CI 1.076-5.704)]. Higher NLR levels also predicted poor functional capacity [NLR>2.26/2.74, HR 3.93(95%CI 1.02-15.12)/3.085(95%CI 1.52-6.26)], hospital readmissions [NLR>2.9/7.6, HR 1.46(95%CI 1.10-1.93)/3.46(95%CI 2.11-5.68)] cardiac resynchronization therapy efficacy [NLR>3.45/unit increase, HR 12.22(95%CI 2.16-69.05)/1.51(95%CI 1.01-2.24)] and appropriate implantable cardioverter defibrillator shocks (NLR>2.93), as well as mortality after left ventricular assist device implantation [NLR>4.4/quartiles, HR 1.67 (95%CI 1.03-2.70)/1.22 (95%CI 1.01-1.47)] or heart transplant (NLR>2.41, HR 3.403(95%CI 1.04-11.14)].
CONCLUSION: Increased NLR in HF patients can be a valuable auxiliary biomarker of severity, and most of all, of poor prognosis.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app